Explore the words cloud of the RADIcAL project. It provides you a very rough idea of what is the project "RADIcAL" about.
The following table provides information about the project.
|Coordinator Country||United Kingdom [UK]|
|Total cost||3˙460˙486 €|
|EC max contribution||3˙460˙486 € (100%)|
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-07-01 to 2020-12-31|
Take a look of project's partnership.
Chronic liver diseases are called 'silent killers', as clinical symptoms only surface at late stages of the disease, when it is not treatable. Non-alcoholic fatty liver disease (NAFLD), a condition defined by fat accumulation in the liver, and its sub-type non-alcoholic steatohepatitis (NASH) are the major forms of liver disease. Untreated NAFLD/NASH can lead to cirrhosis and to liver failure. 450 million people worldwide suffer from fatty liver disease, which carries several health risks, and causes a huge socio-economic burden. At present, the only way of diagnosing and staging disease is with liver biopsy, which is costly, invasive, and carries some risk. Thus, clinicians are reluctant to use it for people suspected of having NAFLD/NASH. In addition, invasive biopsy is not optimal for serial assessment (e.g. monitoring transplant population for signs of liver rejection). Therefore, there is a lack of an accurate and non-invasive method of assessing liver disease and enabling treatment monitoring. Perspectum Diagnostics Ltd (PD) has developed LiverMultiScan, a novel, non-invasive, quantitative Magnetic Resonance Imaging software tool that displays high diagnostic accuracy for the early assessment of liver disease, and can be used for patient stratification. It has recently obtained regulatory clearance, but it requires additional clinical validation to assure its broad market acceptance and reimbursement. Thus, RADIcAL entails two clinical trials: a) a multi-centre randomised health economic study to validate the cost-effectiveness and added value of LiverMultiScan compared to the standard care pathway for chronic liver disease; and (b) a prospective clinical trial to demonstrate the high sensitivity and specificity of LiverMultiScan as a medical support tool for stratifying patients at high risk of liver transplant rejection.
|SOP for data protection||Documents, reports||2020-03-11 15:04:46|
|Data management plan||Documents, reports||2020-03-11 15:04:46|
|Communication plan and updates||Documents, reports||2020-03-11 15:04:46|
Take a look to the deliverables list in detail: detailed list of RADIcAL deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RADICAL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RADICAL" are provided by the European Opendata Portal: CORDIS opendata.
OncoMasTR - Novel Prognostic Assay for Early Stage Breast CancerRead More
Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-needRead More